Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576
Study sponsor: AKARI Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-09-03Actual
Enrollment · participants9Actual
Source updated2025-04-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.